跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NASACORT 55 microgramos/dosis, SUSPENSION PARA PULVERIZACION NASAL - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
NASACORT 55 microgramos/dosis, SUSPENSION PARA PULVERIZACION NASAL
Approved
STANDARD
NASACORT 55 microgramos/dosis, SUSPENSION PARA PULVERIZACION NASAL
Opella Healthcare France S.A.S.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jan 21, 2022
Approval ID
180d6ad4b97fbcc4
Company
Opella Healthcare France S.A.S.
Type
Standard
Approval Details
Approval Id
180d6ad4b97fbcc4
Drug Cima Aemps Name
NASACORT 55 microgramos/dosis, SUSPENSION PARA PULVERIZACION NASAL
Register Number
3400934292293
Holder Company Name
Opella Healthcare France S.A.S.
Marketing Company Name
Difarmed S.L.U.
Authorization Date
2022-01-21
Dosage Form
SUSPENSIÓN PARA PULVERIZACIÓN NASAL
Dose
55µg
Route Of Administration
VÍA NASAL
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
Yes
Company Name
Opella Healthcare France S.A.S.
Active Ingredients
TRIAMCINOLONA ACETONIDO
55 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jan 21, 2022
Approval ID
180d6ad4b97fbcc4
Type
Standard
Back to CIMA-AEMPS Approvals